Adipiplon

Adipiplon
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 7-[(2-(3-fluoropyridin-2-yl)-1H-imidazol-1-yl)methyl]-2-methyl-8-propyl-[1,2,4]triazolo[1,5-c]pyrimidine;
CAS Number	840486-93-3 ;
ChemSpider	9373993 ;
UNII	OPL214POJ1;
KEGG	D08840 ;
ChEMBL	ChEMBL2103791 ;
CompTox Dashboard (EPA)	DTXSID40232944 ;
Chemical and physical data
Formula	C18H18FN7
Molar mass	351.389 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n4c(C)nc1n4cnc(c1CCC)Cn2ccnc2-c3ncccc3F;
	InChI InChI=1S/C18H18FN7/c1-3-5-13-15(22-11-26-17(13)23-12(2)24-26)10-25-9-8-21-18(25)16-14(19)6-4-7-20-16/h4,6-9,11H,3,5,10H2,1-2H3 ; Key:UAMAIHOEGLEXSV-UHFFFAOYSA-N ;
	(what is this?) (verify)

Adipiplon (developmental code name NG2-73) is an anxiolytic drug developed by Neurogen Corporation. It has similar effects to benzodiazepine drugs, but is structurally distinct and classed as a nonbenzodiazepine anxiolytic.

Adipiplon is a subtype-selective GABA_A receptor partial agonist, which binds preferentially to the α₃ subtype. This is significant as while several previous nonbenzodiazepine drugs have been developed that are selective for α_2/3 over the other subtypes, adipiplon is one of the first drugs selected for clinical development which can discriminate between α₂ and α₃, as well as showing a little affinity for the α₁ or α₅ subtypes — alpidem is selective for α₃ over α₂, but still has moderate affinity for α₁, whereas adipiplon is highly α₃-selective with little affinity for either α₁, α₂ or α₅.

Adipiplon was being researched as a potential medication for the treatment of anxiety and insomnia, and in 2008 it was being used in Phase IIb trials.^[1]^[2]^[3] These trials were suspended after significant next-day side effects were discovered.^[4]